FDA authorises restart of the COVID-19 AZD1222 vaccine US phase 3 trial
This article was originally published here
The Food and Drug Administration (FDA) today authorised the restart in the US, following the resumption of trials in other countries in recent weeks. The FDA reviewed all
The post FDA authorises restart of the COVID-19 AZD1222 vaccine US phase 3 trial appeared first on Pharmaceutical Business review.
Leave a Reply
Want to join the discussion?Feel free to contribute!